Delving into the Latest Updates on Etofenamate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Etofenamate (USAN/INN)

+ [4]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

PainInflammation

Inactive Indication-

Originator Organization

Viatris, Inc.

Active Organization

Bayer AG

Viatris, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

DE (21 Feb 1990),

Inflammation

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H18F3NO4

InChIKeyXILVEPYQJIOVNB-UHFFFAOYSA-N

CAS Registry30544-47-9

Our aim was to evaluate the effects of topical analgesic drugs on rapid recovery of joint functions and pain relief in acute ankle injuries.
A total of 100 patients were included in the study and divided into 2 groups as Diclofenac and Etofenamate. The pain scores of the patients were evaluated with the Numeric Rating scale and Wong-Baker scale before and after treatment. Dorsiflexion and plantarflexion active joint movements were measured with a hand-held goniometer for joint function before and after treatment.
We found that ankle sprains were more common in men. In our study, we found that both topical analgesics were effective in improving joint movements and reducing pain.

Start Date01 Jan 2024

Sponsor / Collaborator

Ankara Bilkent City Hospital

EUCTR2021-003778-30-DE / Unknown statusPhase 3

Randomized, controlled, multi-center trial to evaluate the efficacy and safety of Lixim 70 mg wirkstoffhaltiges Pflaster (etofenamate 70 mg medicated plaster) vs. placebo in the local symptomatic and short-term treatment of pain in acute strains, sprains or bruises of soft tissues following blunt trauma, e.g. sports injuries

Start Date29 Dec 2021

Sponsor / Collaborator

Drossapharm AG

PACTR201811864509898 / CompletedPhase 4IIT

The evaluation of the efficiency of etofenamate spray in postoperative cesarean pain: Randomized, double-blind, placebo-controlled study.

Start Date28 Nov 2018

Sponsor / Collaborator-

100 Clinical Results associated with Etofenamate

Login to view more data

100 Translational Medicine associated with Etofenamate

Login to view more data

100 Patents (Medical) associated with Etofenamate

Login to view more data

102

Literatures (Medical) associated with Etofenamate

01 Nov 2024·Biomedical Chromatography

Innovative UPLC technique for concurrent quantification of etofenamate and benzyl nicotinate in the presence of methylparaben and benzyl alcohol in their topical cream: Greens, white, and Six Sigma methodologies

Article

Author: Mahmoud, Osama A. ; Gomaa, Hosni A. ; Omran, Ahmed A. ; Mohamed, Mahmoud A. ; Binsaleh, Ammena Y.

AbstractThe efficacious treatment of muscle and joint pain relies heavily on etofenamate (ETO) and benzyl nicotinate (BN), which possess robust anti‐inflammatory and pain‐relieving properties when paired with methylparaben (MP) or benzyl alcohol (BA). In this study, we have established and validated innovative RP‐UPLC methods for assessing ETO and BN in the presence of MP or BA in their dosage forms, employing eight green tools to evaluate their eco‐friendliness and effectiveness. Reversed phase‐ultra‐performance liquid chromatography (RP‐UPLC) technique employs a flow rate of 0.3 mL/min on Waters Acquity UPLC BEH Column (C18, 1.7 μm, 100 mm × 2.1 mm), detection at 254 nm using a photo diode array (PDA) detector and mobile phase of 0.05 M KH2PO4 buffer, acetonitrile, and methanol (50:15:35, v/v/v) adjusted pH 6.0 with 0.2% triethylamine. For ETO, BN, MP, and BA, the calibration curves were linear and ranged from 0.005 to 1.0, from 0.001 to 0.2, from 0.002 to 0.08, and from 0.0001 to 0.1 mg/mL, respectively. The correlation value was 0.9999, and the accuracy findings ranged from 98.81% to 100.56%. Consequently, the methodology has been successfully implemented in assay testing for the pharmaceuticals in the presence of the MP or BA, demonstrating the high selectivity of these approaches. The present study presents the Blue Applicability Grade Index (BAGI), an innovative approach that complements green metrics in practical white analytical chemistry. According to the International Council for Harmonisation (ICH) criteria, the procedures were effectively validated.

01 Apr 2024·Analytica Chimica Acta

First electrochemical investigation and determination of non-steroidal anti-inflammatory drug etofenamate using disposable pencil graphite electrode with voltammetric techniques

Article

Author: Aral, Hayriye ; Levent, Abdulkadir ; Aslan, Mehmet ; Yurdem, Aysel

In this study, the electrochemical properties of etofenamate, an active ingredient belonging to the non-steroidal anti-inflammatory drug group, were investigated using cyclic voltammetry (CV) and square wave voltammetry (SW) techniques on a disposable pencil graphite electrode (PGE). With the CV technique, reversible voltammetric waves of around +0.470 V and irreversible voltammetric waves of around +1.02 V were produced on the PGE. An environmentally friendly, selective and highly sensitive SW voltammetric method was developed using disposable PGE. This voltammetric method gave very good analytical working range on PGE in PBS (pH = 3.0) medium at concentrations ranging from 0.017 μM to 0.306 μM. The LOD value of this analytical method in PBS (pH = 3.0) medium was calculated as 0.0011 μM (0.406 μg L^-1). The developed voltammetric method was successfully applied to urine and drug samples. The results of the voltammetric method were compared with the results of the spectrophotometric method. The results were found to be compatible with each other.

01 Sep 2023·Taiwanese journal of obstetrics & gynecology

The evaluation of the efficacy of etofenamate spray in postoperative cesarean pain: Randomized, double-blind, placebo-controlled trial.

Article

Author: Kulaksiz, Deniz ; Sahal, Safia Omar ; Bakİ Erİn, Kübra ; Kartal, Seyfi ; Erİn, Recep

OBJECTIVEIt was aimed to investigate the effect of etofenamate spray to be applied around the postoperative incision on pain control in cesarean section in this trial.MATERIAL AND METHODSThis was a prospective, randomized, double-blind, and placebo-controlled trial. 187 patients (93 cases and 94 controls) were recruited for the study. In the trial group, we applied the etofenamate spray (Doline® 50 ml) after closing the cesarean skin incision and go on four times a day on the skin incision for 24 h. In the control group, we applied a placebo. All patients received paracetamol IV (Paracerol®) as standard analgesic doses. If analgesia was insufficient, tramadol (Contramal®) 50 mg IV doses were added and recorded. A visually analog pain scale (VAS) was performed on both groups at 6-12-18-24th hours. Independent t-tests were performed for data showing normal distributions.RESULTSThere were no significant differences in the mean of differences VAS scores between the two groups at 6-12, and 6-18 h. However, a significant difference was obtained in the mean of differences VAS score at the 6-24th hour (p < 0.05). When the groups were compared in terms of additional paracetamol need, a significant difference was found again (p < 0.05). There was no significant difference between the groups in terms of tramadol need.CONCLUSIONPostoperative administration of etofenamate spray provided an analgesic effect at 24 h and additional analgesic usage decreased. Postoperative analgesia can also be used by administering NSAIDs around the cesarean section incision. In this way, the side effects of other systemic analgesics are avoided.CLINICAL TRIAL IDPACTR201811864509898. CLINICAL TRIAL WEB LINK: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5745.

100 Deals associated with Etofenamate

Login to view more data